Literature DB >> 19291344

BMD, clinical risk factors and their combination for hip fracture prevention.

H Johansson1, J A Kanis, A Oden, O Johnell, E McCloskey.   

Abstract

SUMMARY: This study examined the effects of the use of clinical risk factors (CRFs) alone, BMD alone or the combination using the FRAX tool for the detection of women at risk of hip fracture. BMD tests alone selected women at higher risk and a greater number of hip fracture cases were identified compared to the use of CRFs alone. The combined use of CRFs and BMD identified fewer women above a threshold risk than the use of BMD alone, but with a higher hip fracture risk and thus had the more favourable positive predictive value (PPV) and number needed to treat (NNT).
INTRODUCTION: Algorithms have recently become available for the calculation of hip fracture probability from CRFs with and without information on femoral neck BMD. The aim of this study was to examine the effects of the use of CRFs alone, BMD alone or their combination using the FRAX tool for the detection of women at risk of hip fracture.
METHODS: Data from 10 prospective population based cohorts, in which BMD and CRFs were documented, were used to compute the 10-year probabilities of hip fracture calibrated to the fracture and death hazards of the UK. The effects of the use of BMD tests were examined in simulations where BMD tests were used alone, CRFs alone or their combined use. The base case examined the effects in women at the age of 65 years. The principal outcome measures were the number of women identified above an intervention threshold, the number of hip fracture cases that would be identified, the positive predicted value and the NNT to prevent a hip fracture during a hypothetical treatment with an effectiveness of 35% targeted to those above the threshold fracture risk. We also examined BMD values in women selected for treatment. Sensitivity analysis examined the effect of age and limited use of BMD resources.
RESULTS: BMD tests alone selected women at higher risk of hip fracture than the use of CRFs alone (6.1% versus 5.3%). BMD tests alone also identified a greater number of hip fracture cases (219/1,000) compared to the use of CRFs alone (140/1,000). The combined use of CRFs and BMD identified fewer women above a threshold risk than the use of BMD alone (168/1,000 versus 219/1,000, respectively), but with a higher hip fracture risk (PPV, 8.6% versus 6.1%), and consequently a lower number needed to treat (NNT) (33 versus 47). In sensitivity analyses, the PPV and NNT were always better for the combination than either BMD or CRFs alone across all ages studied (50-70 years).
CONCLUSIONS: The use of FRAX in combination with BMD increases the performance characteristics of fracture risk assessment.

Entities:  

Mesh:

Year:  2009        PMID: 19291344     DOI: 10.1007/s00198-009-0845-x

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  42 in total

1.  The burden of osteoporotic fractures: a method for setting intervention thresholds.

Authors:  J A Kanis; A Oden; O Johnell; B Jonsson; C de Laet; A Dawson
Journal:  Osteoporos Int       Date:  2001       Impact factor: 4.507

2.  Guidelines for diagnosis and management of osteoporosis. The European Foundation for Osteoporosis and Bone Disease.

Authors:  J A Kanis; P Delmas; P Burckhardt; C Cooper; D Torgerson
Journal:  Osteoporos Int       Date:  1997       Impact factor: 4.507

3.  Risk of hip fracture according to the World Health Organization criteria for osteopenia and osteoporosis.

Authors:  J A Kanis; O Johnell; A Oden; B Jonsson; C De Laet; A Dawson
Journal:  Bone       Date:  2000-11       Impact factor: 4.398

4.  At what hip fracture risk is it cost-effective to treat? International intervention thresholds for the treatment of osteoporosis.

Authors:  F Borgström; O Johnell; J A Kanis; B Jönsson; C Rehnberg
Journal:  Osteoporos Int       Date:  2006-07-18       Impact factor: 4.507

5.  FRAX and the assessment of fracture probability in men and women from the UK.

Authors:  J A Kanis; O Johnell; A Oden; H Johansson; E McCloskey
Journal:  Osteoporos Int       Date:  2008-02-22       Impact factor: 4.507

6.  Alcohol intake as a risk factor for fracture.

Authors:  John A Kanis; Helena Johansson; Olof Johnell; Anders Oden; Chris De Laet; John A Eisman; Huibert Pols; Alan Tenenhouse
Journal:  Osteoporos Int       Date:  2004-09-29       Impact factor: 4.507

7.  International variations in hip fracture probabilities: implications for risk assessment.

Authors:  John A Kanis; Olof Johnell; Chris De Laet; Bengt Jonsson; Anders Oden; Alan K Ogelsby
Journal:  J Bone Miner Res       Date:  2002-07       Impact factor: 6.741

Review 8.  Diagnosis of osteoporosis and assessment of fracture risk.

Authors:  John A Kanis
Journal:  Lancet       Date:  2002-06-01       Impact factor: 79.321

9.  Relative contributions of bone density, bone turnover, and clinical risk factors to long-term fracture prediction.

Authors:  L Joseph Melton; Cynthia S Crowson; W Michael O'Fallon; Heinz W Wahner; B Lawrence Riggs
Journal:  J Bone Miner Res       Date:  2003-02       Impact factor: 6.741

10.  A family history of fracture and fracture risk: a meta-analysis.

Authors:  J A Kanis; H Johansson; A Oden; O Johnell; C De Laet; J A Eisman; E V McCloskey; D Mellstrom; L J Melton; H A P Pols; J Reeve; A J Silman; A Tenenhouse
Journal:  Bone       Date:  2004-11       Impact factor: 4.398

View more
  44 in total

1.  Height loss predicts subsequent hip fracture in men and women of the Framingham Study.

Authors:  Marian T Hannan; Kerry E Broe; L Adrienne Cupples; Alyssa B Dufour; Margo Rockwell; Douglas P Kiel
Journal:  J Bone Miner Res       Date:  2012-01       Impact factor: 6.741

2.  A FRAX® model for the assessment of fracture probability in Belgium.

Authors:  H Johansson; J A Kanis; E V McCloskey; A Odén; J-P Devogelaer; J-M Kaufman; A Neuprez; M Hiligsmann; O Bruyere; J-Y Reginster
Journal:  Osteoporos Int       Date:  2010-03-30       Impact factor: 4.507

3.  The use of routine non density calibrated clinical computed tomography data as a potentially useful screening tool for identifying patients with osteoporosis.

Authors:  Christopher John Burke; Manjiri M Didolkar; Huiman X Barnhart; Emily N Vinson
Journal:  Clin Cases Miner Bone Metab       Date:  2016-10-05

4.  The distribution of FRAX(®)-based probabilities in women from Japan.

Authors:  John A Kanis; Helena Johansson; Anders Odén; Eugene V McCloskey
Journal:  J Bone Miner Metab       Date:  2012-08-22       Impact factor: 2.626

5.  Personalized medicine for osteoarthritis: where are we now?

Authors:  Allen Dale Sawitzke
Journal:  Ther Adv Musculoskelet Dis       Date:  2013-04       Impact factor: 5.346

6.  Importance of bone mineral density measurements in evaluating fragility bone fracture risk in Asian Indian men.

Authors:  K Kuruvilla; A M Kenny; L G Raisz; J E Kerstetter; R S Feinn; T V Rajan
Journal:  Osteoporos Int       Date:  2010-05-06       Impact factor: 4.507

7.  Comparison between frailty index of deficit accumulation and fracture risk assessment tool (FRAX) in prediction of risk of fractures.

Authors:  Guowei Li; Lehana Thabane; Alexandra Papaioannou; Jonathan D Adachi
Journal:  Bone       Date:  2015-04-25       Impact factor: 4.398

8.  FRAX-based intervention and assessment thresholds for osteoporosis in Iran.

Authors:  P Khashayar; A Keshtkar; A Ostovar; B Larijani; H Johansson; N C Harvey; M Lorentzon; E McCloskey; J A Kanis
Journal:  Osteoporos Int       Date:  2019-08-01       Impact factor: 4.507

9.  Variation in risk factors for fractures at different sites.

Authors:  Jennifer L Kelsey; Elizabeth J Samelson
Journal:  Curr Osteoporos Rep       Date:  2009-12       Impact factor: 5.096

Review 10.  A systematic review of intervention thresholds based on FRAX : A report prepared for the National Osteoporosis Guideline Group and the International Osteoporosis Foundation.

Authors:  John A Kanis; Nicholas C Harvey; Cyrus Cooper; Helena Johansson; Anders Odén; Eugene V McCloskey
Journal:  Arch Osteoporos       Date:  2016-07-27       Impact factor: 2.617

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.